Overview

To Evaluate the Effect of Ritonavir or Omeprazole on the Pharmacokinetics of Samatasvir (IDX719) in Healthy Participants (MK-1894-006)

Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
0
Participant gender:
All
Summary
This study is designed to evaluate the potential for an effect of Ritonavir (NorvirĀ®) or omeprazole (PrilosecĀ®) on the pharmacokinetics of samatasvir and to assess the safety and tolerability of the study drugs when administered alone and in combination in healthy participants.
Phase:
Phase 1
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Omeprazole
Ritonavir
Criteria
Inclusion Criteria:

- Read and signed the written informed consent form (ICF) after the nature of the study
has been fully explained.

- All participants of childbearing potential must agree to use a double method of birth
control (one of which must be a barrier) from Screening through at least 90 days after
the last dose of the study drug.

Exclusion Criteria:

- Pregnant or breastfeeding.